Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)

<b>Background:</b> Canakinumab, a humanized anti-IL-1β monoclonal antibody, is known for its ability to suppress IL-1β-mediated inflammation. However, continuous monitoring of its safety remains essential. Thus, we comprehensively evaluated the safety signals of canakinumab by data minin...

Full description

Saved in:
Bibliographic Details
Main Authors: Weidong Zhang, Yunzhou Chen, Zeyu Yao, Mengling Ouyang, Minghui Sun, Shupeng Zou
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Pharmaceuticals
Subjects:
FAERS
adverse events
pharmacovigilance
canakinumab
data mining
Online Access:https://www.mdpi.com/1424-8247/18/1/114
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1424-8247/18/1/114

Similar Items